Immunotherapy and Lymphoma Treatment

Dr. Bruce D. Cheson, MD, FACP, FAAAS of Georgetown University Hospital Lombardi Comprehensive Cancer Center, discusses how immunotherapy may replace chemotherapy as an effective treatment for certain types of lymphoma. Watch to learn more about the various types of immunotherapy and the ways in which it is used to treat lymphomas.

**UPDATE: Since the filming of this video, two immunotherapy treatments have been approved by the FDA:

1. CAR T-Cell therapy, axicabtagene ciloleucel (YescartaTM, Kite, a Gilead Company), was approved by the FDA to treat patients with large B-cell lymphoma who have relapsed or have not responded to at least two previous lines of therapy. Only the second gene therapy approved by the FDA, this approval of the chimeric antigen receptor (CAR) T cell therapy, represents the first indication of gene therapy for lymphoma patients.

2. Nivolumab (Opdivo) was approved by the FDA for the treatment of patients with classical Hodgkin lymphoma (cHL) that have relapsed or progressed after an autologous stem cell transplant and who have been treated with brentuximab vedotin (Adcetris) post-transplant. In addition,

3. Pembrolizumab (Keytruda) was approved by the FDA for the treatment of patients with refractory classical hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.


The Lymphoma Research Foundation’s (LRF) mission is to eradicate lymphoma and serve all those impacted by this blood cancer.
Learn More:
http://www.lymphoma.org/
http://www.facebook.com/lymphomacommunity
http://twitter.com/lymphoma